Drugs / MIDRIX4-LUNG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04082182 | Aug 2019 → Jun 2021 | non-small cell lung carcinoma | University Hospital, Ghent | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIDRIX4-LUNG | “Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks” NCT04082182 ↗ |
| Modality | Cell therapy | “a novel tetravalent autologous dendritic cell vaccine” NCT04082182 ↗ |
| Route | Intravenous | “MIDRIX4-LUNG administered i.v.” NCT04082182 ↗ |